Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819423 | 0.81 | MEN1 (0.41) | ALDH1A1KMT2AHPGD | |
| SCHEMBL16426719 | 0.71 | CYP2C9 (0.44) | PDE2ATSHRCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL28931321 | 0.62 | SLC6A4 (0.53) | SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL2992858 | 0.62 | SLC6A4 (0.53) | SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2 | |
| Hydrogen Peroxide SCHEMBL6286755 | 0.61 | CYP1A2 (0.56) | TSHRSLC6A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL2333290 | 0.61 | ALDH1A1 (0.56) | SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL29774251 | 0.61 | ALDH1A1 (0.56) | SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL4556534 | 0.61 | ALDH1A1 (0.56) | TSHRSLC6A4CYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL12047423 | 0.61 | ALDH1A1 (0.43) | SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL20307892 | 0.61 | ALDH1A1 (0.43) | SLC6A4CYP2C9CYP2C19ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153810-B2 | Alkylidene complexes of ruthenium containing N-heterocyclic carbene ligands; use as highly active, selective catalysts for olefin metathesis | EVONIK DEGUSSA GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20110282068-A1 | ALKYLIDENE COMPLEXES OF RUTHENIUM CONTAINING N-HETEROCYCLIC CARBENE LIGANDS; USE AS HIGHLY ACTIVE, SELECTIVE CATALYSTS FOR OLEFIN METATHESIS | EVONIK DEGUSSA GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20080207911-A1 | ALKYLIDENE COMPLEXES OF RUTHENIUM CONTAINING N-HETEROCYCLIC CARBENE LIGANDS; USE AS HIGHLY ACTIVE, SELECTIVE CATALYSTS FOR OLEFIN METATHESIS | EVONIK DEGUSSA GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7378528-B2 | Alkylidene complexes of ruthenium containing N-heterocyclic carbene ligands; use as highly active, selective catalysts for olefin metathesis | EVONIK DEGUSSA GMBH (DE) | 2008-05-27 | — | — | US | disclosed |
| US-20080009598-A1 | ALKYLIDENE COMPLEXES OF RUTHENIUM CONTAINING N-HETEROCYCLIC CARBENE LIGANDS; USE AS HIGHLY ACTIVE, SELECTIVE CATALYSTS FOR OLEFIN METATHESIS | DEGUSSA AG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20050013150-A2 | ALKYLIDENE COMPLEXES OF RUTHENIUM CONTAINING N-HETEROCYCLIC CARBENE LIGANDS; USE AS HIGHLY ACTIVE, SELECTIVE CATALYSTS FOR OLEFIN METATHESIS | Aventis Research @$amp; Technologies GmbH @$amp; Co. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20040095792-A1 | Alkylidene complexes of ruthenium containing N-heterocyclic carbene ligands; use as highly active, selective catalysts for olefin metathesis | HERRMANN WOLFGANG ANTON (DE) | 2004-05-20 | — | — | US | disclosed |
| US-6635768-B1 | Inexpensive, highly active catalysts; high tolerance toward a variety of functional groups but also a wide range of possible variations in the ligand sphere | DEGUSSA AG (DE) | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282068-A1 | ALKYLIDENE COMPLEXES OF RUTHENIUM CONTAINING N-HETEROCYCLIC CARBENE LIGANDS; USE AS HIGHLY ACTIVE, SELECTIVE CATALYSTS FOR OLEFIN METATHESIS | CBR1, NR2E1, OXER1 | PDE2A 4864/4885TSHR 590/4885SLC6A4 1378/4885 |
| US-20080207911-A1 | ALKYLIDENE COMPLEXES OF RUTHENIUM CONTAINING N-HETEROCYCLIC CARBENE LIGANDS; USE AS HIGHLY ACTIVE, SELECTIVE CATALYSTS FOR OLEFIN METATHESIS | CBR1, NR2E1, OXER1 | PDE2A 4867/4885TSHR 614/4885SLC6A4 1477/4885 |
| US-20080009598-A1 | ALKYLIDENE COMPLEXES OF RUTHENIUM CONTAINING N-HETEROCYCLIC CARBENE LIGANDS; USE AS HIGHLY ACTIVE, SELECTIVE CATALYSTS FOR OLEFIN METATHESIS | CBR1, NR2E1, OXER1 | PDE2A 4867/4885TSHR 614/4885SLC6A4 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.